# Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)

> **NCT00400153** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1480 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Atrovent Respimat (20 mcg)
- **DRUG:** COMBIVENT MDI (36/206 mcg)
- **DRUG:** Combivent Respimat (20 mcg/100 mcg)
- **DRUG:** Placebo via corresponding inhaler for blinding purposes

## Key facts

- **NCT ID:** NCT00400153
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-04
- **Final completion:** —
- **Target enrollment:** 1480 (ACTUAL)
- **Last updated:** 2014-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00400153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00400153, "Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00400153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*